Citi: Maintains TIGERMED Outperform Rating, Moderate Recovery in Q3
Citi released a research report stating that Tigermed's third-quarter performance reflects a moderate recovery in the company's business. Although profit margins remain under pressure, it is expected that products may rebound in 2026. The revenue forecasts for 2025 to 2027 are largely maintained, while net profit forecasts are adjusted up by 28.9%, down by 14.6%, and down by 14.1%, respectively, to reflect the profit margin outlook. The target price is lowered from HKD 58.9 to HKD 52.1, while maintaining an "outperform" rating
According to the Zhitong Finance APP, Citi has released a research report stating that Tigermed (03347) third-quarter performance reflects a moderate recovery in the company's business. Although profit margins remain under pressure, it is expected that products may rebound in 2026. The revenue forecasts for 2025 to 2027 are largely maintained, while net profit forecasts are adjusted up by 28.9%, down by 14.6%, and down by 14.1%, respectively, to reflect the profit margin outlook. The target price is lowered from HKD 58.9 to HKD 52.1, while maintaining an "outperform" rating
